Exacerbation Rate Reduction With Mepolizumab Stratified by Maintenance Oral Corticosteroids Use and Eosinophil Levels: A Post Hoc Analysis of the DREAM and MENSA Studies

Exacerbation Rate Reduction With Mepolizumab Stratified by Maintenance Oral Corticosteroids Use and Eosinophil Levels: A Post Hoc Analysis of the DREAM and MENSA Studies

Bibliographic Details
Main Authors: Bañas, D. (Author), Bobolea, I. (Author), de Andrés, A.I (Author), Joksaite, S. (Author), Melero, C. (Author), Sánchez-Herrero, G. (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Subjects:
Adrenal Cortex Hormones
antiasthmatic agent
Anti-Asthmatic Agents
Antibodies, Monoclonal, Humanized
Asthma
corticosteroid
eosinophil
Eosinophils
Exacerbations
human
Humans
mepolizumab
Mepolizumab
monoclonal antibody
Oral corticosteroids (OCS)
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items